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Background. Previous research indicates that a combination vaccine targeting different stages of the malaria life cycle is likely
to provide the most effective malaria vaccine. This trial was the first to combine two existing vaccination strategies to produce
a vaccine that induces immune responses to both the pre-erythrocytic and blood stages of the P. falciparum life cycle.
Methods. This was a Phase I/IIa study of a new combination malaria vaccine FFM ME-TRAP+PEV3A. PEV3A includes peptides
from both the pre-erythrocytic circumsporozoite protein and the blood-stage antigen AMA-1. This study was conducted at the
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK. The participants were healthy, malaria
naı¨ve volunteers, from Oxford. The interventions were vaccination with PEV3A alone, or PEV3A+FFM ME-TRAP. The main
outcome measure was protection from malaria in a sporozoite challenge model. Other outcomes included measures of parasite
specific immune responses induced by either vaccine; and safety, assessed by collection of adverse event data. Results. We
observed evidence of blood stage immunity in PEV3A vaccinated volunteers, but no volunteers were completely protected
from malaria. PEV3A induced high antibody titres, and antibodies bound parasites in immunofluorescence assays. Moreover,
we observed boosting of the vaccine-induced immune response by sporozoite challenge. Immune responses induced by FFM
ME-TRAP were unexpectedly low. The vaccines were safe, with comparable side effect profiles to previous trials. Although
there was no sterile protection two major observations support an effect of the vaccine-induced response on blood stage
parasites: (i) Lower rates of parasite growth were observed in volunteers vaccinated with PEV3A compared to unvaccinated
controls (p = 0.012), and this was reflected in the PCR results from PEV3A vaccinated volunteers. These showed early control of
parasitaemia by some volunteers in this group. One volunteer, who received PEV3A alone, was diagnosed very late, on day 20
compared to an average of 11.8 days in unvaccinated controls. (ii). Morphologically abnormal parasites were present in the
blood of all (n = 24) PEV3A vaccinated volunteers, and in only 2/6 controls (p = 0.001). We describe evidence of vaccine-induced
blood stage efficacy for the first time in a sporozoite challenge study. Trial Registration. ClinicalTrials.Gov NCT00408668
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INTRODUCTION
Malaria represents a huge burden of global disease, affecting
approximately 40% of the world’s population. It is estimated that
there were 515 million clinical episodes of P. falciparum malaria in
2002 [1] and at least a million people die from the disease
annually. An effective vaccine could have an enormous impact on
this problem, both for people in the developing world and for
those travelling to malaria endemic countries [1,2]. It has long
been recognised that a multi-stage vaccine is likely to provide the
greatest level of protection against P. falciparum malaria [3,4].
This trial is the first to evaluate clinically the combined
administration of two promising malaria vaccines targeting
different life-cycle stages: FP9/MVA ME-TRAP and PEV3A.
Recent studies in murine malaria, assessing the combination of an
anti-sporozoite antibody-inducing vaccine with an anti-liver-stage
T cell-inducing vaccine [5], suggested that combining these
vaccines could be synergistic leading to enhanced protection.
Fowlpox strain FP9 and modified vaccinia virus Ankara (MVA)
vectors expressing the pre-erythrocytic antigen thrombospondin-
related adhesion protein (TRAP), fused to a multi-epitope (ME)
string were developed by the University of Oxford [6]. When used
in a heterologous prime-boost regimen in Oxford these vaccines
induced strong T cell responses, and significantly reduced parasite
numbers emerging from the liver by about 90% [7], with some
individuals completely protected from malaria challenge. This
protection persisted in one individual on two further challenges at
14 and 20 months after vaccination [8]. These encouraging data
led to the assessment of FP9-MVA ME-TRAP in a series of phase
I/II studies in adults and in children in Gambia [9] and in Kenya,
where lower T cell immunogenicity has been observed [10].
PEV3A was developed by Pevion Biotech in collaboration with
the Swiss Tropical Institute [11,12]. This vaccine uses an influenza
virosome-based technology, which has been approved for human
use in more than 40 countries. Initially developed as an influenza
vaccine itself, it can also be used as an antigen delivery system (e.g.
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hepatitis A vaccine) [13]. PEV3A is a virosomal formulation of two
malaria antigens. These are peptides derived from the circum-
sporozoite (CS) protein and apical membrane antigen-1 (AMA-1)
of the K1 isolate of P. falciparum. The peptide from the CS protein
is an internally cyclised double loop of 5 NPNA repeats, the major
B cell epitope of the CS protein [12]. Antibodies against this
peptide inhibit sporozoite motility and invasion capability. The
peptide from AMA-1 mimics the semi-conserved loop I of domain
III and has been found capable of inducing antibodies that, as
monoclonal antibodies, impair the growth of blood stage P.
falciparum parasites [11]. Both peptides are linked to phosphati-
dylethanolamine (PE), which intercalates into the virosomal
membrane, thereby displaying the attached peptides on the
surface of the virosomes. Each peptide was incorporated into
virosomes separately. Both vaccine components applied alone and
in combination have been previously used in a Phase I study in
Switzerland and found to be safe and immunogenic [12,14]. We
report a Phase I/IIa sporozoite challenge study that indicates that
this bivalent peptide vaccine induces immune responses that have
an inhibitory effect on blood stage parasites.
METHODS
Participants
The protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol S1
and Addendum S1. Healthy malaria naı¨ve adult subjects aged 18–
50 years were recruited in the Oxford area from August 2005 and
underwent medical screening as previously described [15]. Exclusion
criteria included a prior history of malaria, immunosuppression,
epilepsy, infection with hepatitis B, hepatitis C or HIV, pregnancy,
drug or alcohol abuse, significant psychiatric disorder or other
significant illness. All vaccinations and follow up visits took place in
the outpatients unit at the Centre for Clinical Vaccinology and
Tropical Medicine, part of the University of Oxford at the Churchill
Hospital. The malaria challenge was performed in the insectary in the
Alexander Fleming Building, Imperial College London.
Ethics
The study received ethical approval from the Oxfordshire
Research Ethics Committee A, the approval is available as
supporting information Ethics Approval Letter S1; and was
conducted under a Clinical Trial Authorisation from the MHRA.
An Independent Local Safety Monitor was appointed in Oxford.
All volunteers provided fully informed consent to participate in
this study by signing a written consent form, prior to any study
procedures. A copy of the consent form is available as supporting
document Consent Form S1. The trial was conducted according
to GCP and the principles of The Declaration of Helsinki, and was
externally monitored by Appledown Clinical Research Ltd. The
study design is represented pictorially in Figure 1.
Interventions
PEV3A is a virosomal vaccine preparation manufactured by Pevion
Biotech Ltd., Switzerland. The vaccine carries two synthetic P.
falciparum peptide-PE conjugates derived from the circumsporozoite
protein (UK-39) and the apical membrane antigen-1 (AMA49-C1).
The sequences of both of these peptides were derived from the K1
isolate of P. falciparum. PEV3A was imported from Switzerland in
vials of 0.5 mL containing 50 mg of virosomally-formulated
AMA49-C1 (PEV301) and 10 mg of virosomally-formulated UK-
39 (PEV302) in phosphate buffered saline (pH 7.4), and stored at +2
to +8uC. This dose was selected following a preliminary phase I study
[14] and was shown to be immunogenic. ME-TRAP is a multiple
epitope string including fourteen CD8+T cell epitopes, one CD4+T
cell epitope, and two B cell epitopes from six pre-erythrocytic P.
falciparum antigens fused to the N-terminus of TRAP as previously
described [6]. The ME string includes copies of the B cell epitope
NANP sequence derived from the circumsporozoite protein, also
used in UK39 in PEV3A, as well as 3 CD8 and one CD4 T cell
epitopes, but no AMA-1 derived epitopes. For more detail see [6].
FP9 and MVA ME-TRAP were manufactured by a contract
manufacturer (IDT, Germany). MVA and FP9 ME-TRAP were
stored at 220uC and allowed to thaw prior to administration. The
potency of these vaccines was tested prior to the trial in a
standardised assay on Balb/c mice, 14 days following administration
of the vaccine; peptide specific ELISPOT responses were measured
in splenic lymphocytes. 24 volunteers were enrolled into the study,
with an additional 6 unvaccinated controls for the malaria challenge.
Group 1 volunteers received three doses of PEV3A 0.5 mL (P) given
intramuscularly at baseline, 4 weeks later and 8 weeks. Group 2
volunteers received a combination of PEV3A 0.5 mL given
intramuscularly (P) and FP9 ME-TRAP 16108 plaque forming
units (pfu) given intradermally (F), at baseline; (P) and (F) 4 weeks
later; and (P) and MVA ME-TRAP 1.56108 pfu given intradermally
(M) at 8 weeks. Intramuscular injections were given into the left
deltoid; intradermal injections were administered into the skin over
the right deltoid. Up to 80 ml of blood was drawn at day 0, 7, 28, 35,
56, 63, day of challenge (day 70), challenge+7 days (day 77),
challenge+35 days (day 105) and challenge+90 days (day 160) for
safety assessment and measurement of immunogenicity.
Objectives
This trial had 3 objectives; firstly, to assess protection against P.
falciparum sporozoite challenge following immunisation with the
virosomal vaccine PEV3A alone or in combination with FP9-
MVA ME-TRAP; secondly, to evaluate the immunogenicity of
these regimes with measures of anti parasite immunity and,
thirdly, to assess the safety of these vaccination regimes.
Outcomes
1. Vaccine efficacy The primary outcome was protection
against malaria infection in a P. falciparum sporozoite challenge
model. To assess the efficacy of the vaccines the 24 vaccinated
subjects and 6 unvaccinated infectivity control subjects underwent
experimental challenge with Plasmodium falciparum, fourteen days
after the final vaccination. Laboratory-reared Anopheles stephensi
mosquitoes were infected with the chloroquine-sensitive 3D7
strain of P. falciparum parasites in an adapted model [16] as
described before [6], to assess the efficacy of the vaccines. From
the evening of day 6 subjects attended clinic twice daily for review
Figure 1. Study Design. P=Vaccination with PEV3A, F = Vaccination
with FP9 ME-TRAP, M=Vaccination with MVA ME-TRAP, C = Sporozoite
challenge
doi:10.1371/journal.pone.0001493.g001
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of symptoms, vital signs monitoring (pulse, blood pressure and oral
temperature) and withdrawal of 3 mL of blood for thick film and
PCR analysis. Field’s stain thick films were examined immediately
by experienced microscopists for the appearance of viable
parasites. A minimum of 200 high power fields were examined
before a subject was declared slide negative. Subjects who reached
day 15 without blood film evidence of malaria infection were
followed up daily until day 21. All subjects were treated
immediately with Riamet (artemether 20 mg, lumefantrine
120 mg, Novartis) on diagnosis of malaria by the identification of
a viable parasite on thick film. Subjects returned to clinic on two
consecutive days for negative blood films post treatment. During the
challenge follow-up period blood samples were analysed by PCR in
real time (method discussed in [17]), the clinicians assessing the
subjects were blinded to the results. Efficacy was assessed by
measuring the number of subjects who developed malaria infection
and the time between exposure and parasitaemia as detected by
thick-film blood smear, as well as measurement of parasite growth
rates by PCR. Comparisons were made between the two vaccine
groups and between all vaccinated volunteers and unvaccinated
controls. Parasite growth rates were calculated using a method
previously described [18]. This method is based on a statistical model
of parasite distribution, using a convolution of two probability
density functions to estimate the numbers of parasites present in the
blood and being sequestered at any time. The model was coded into
an Excel TM spreadsheet, and the in-built Solver minimization
routine was used to estimate the best solution by minimization of the
squared difference between calculated and predicted values.
2. Immunogenicity Vaccine immunogenicity was assessed
by IFN-c ELISPOT and ELISA for vaccine specific antibodies.
ELISPOT was performed on PBMCs obtained from each
volunteer at the above-described time points as reported
previously [19]. Anti-UK-39 and anti-AMA49-C1 antibodies
were measured by ELISA. ELISA polysorp microtitre plates
(Nunc, Dr. Grogg, Stetten-Deiswill, Switzerland) were coated at
4uC overnight with 10 mg/ml AMA49-C1 (for PEV301) or UK-39
(for PEV302) in PBS, pH 7.4. Wells were then blocked with 5%
milk powder in PBS for 2 h at 37uC followed by three washes with
PBS containing 0.05% Tween-20. Plates were then incubated with
two-fold serial dilutions of human serum starting with 1:50 in PBS
containing 0.05% Tween-20 and 0.5% milk powder for 2 h at
37uC. After washing, the plates were incubated with horseradish-
peroxidase-conjugated goat anti-human IgG antibodies (KPL,
Socochim, Lausanne, Switzerland) (1:2000 in PBS containing
0.05% Tween-20) for 1 h at 37uC and then washed. 1, 2-
Diaminobezene substrate (OPD) (20 mg/tablet (Fluka, Sigma,
Buchs, Switzerland)) in citrate-buffer (4 mg/ml OPD)+0.01%
H2O2 was added and incubated at room temperature. After
10 minutes the reaction was stopped by addition of sulphuric acid
(final concentration 0.5M (Merck, Darmstadt, Germany)). The
optical density (OD) of the reaction product was recorded at
492 nm using a microplate reader (SpectraMax plus, Bucher
Biotech, Basel, Switzerland). Titration curves were registered using
Softmax PRO software. Endpoint titres were calculated by
comparing the ELISA OD of the test serum with the ELISA
OD of a negative serum pool. The endpoint titre is the last serum
dilution where the ODtest sera$26ODnegative serum.
Avidity index (concentration of thiocyanate leading to the
dissociation of 50% of the bound IgG in ELISA) was measured by
adding serial dilutions of ammonium-thiocyanate after serum
incubation (triplicates at half max saturation), leading to partial
dissociation of bound antibodies [20]. Western blotting with a lysate
of P. falciparum (strain NF54) infected A. stephensi salivary glands, or a
lysate of in vitro cultivated P. falciparum (strain K1; schizont stage)
blood stage parasites, was performed to measure anti-CS protein or
anti-AMA-1 IgG seroconversion at a serum dilution of 1:100.
Immunofluorescent antibody assays (IFA) were used to measure
anti-parasite IgG endpoint titres (defined as last serum dilution
where a staining of the parasite is visible). IFA with a suspension of
P. falciparum (strain NF54) infected A. stephensi salivary glands and
IFA with a suspension of synchronised P. falciparum (strain K1;
schizont stage) infected red blood cells, was used to assess anti-
sporozoite and anti-blood stage endpoint titres, respectively.
Western blotting and IFA are described in more detail in [11,12].
Positive and negative sera from a phase 1 trial with PEV301 and
PEV302 [14] were used as controls for ELISA, IFA and Western
blotting.
3. Safety The outcome of vaccine safety was assessed by
collection of local and systemic adverse events. Each subject was
observed for at least 30 minutes after vaccination, and underwent
clinical review 2, 7 and 28 days after each vaccination for
reporting of solicited and unsolicited adverse events. Subjects also
completed a diary card every day for the first 7 days after each
vaccination. Full blood count and biochemistry (urea, electrolytes,
alanine aminotransferase, bilirubin, alkaline phosphatase,
albumin) was performed at day 0, 7, 28, 35, 56, 63, day of
challenge (day 77), challenge+7 days (day 84), challenge+35 days
(day 112) and challenge+90 days (day 167).
Inhibition assays Plasma samples were shipped to Carole
Long at the NIH for parasite Growth Inhibition Assay (GIA)
analysis as described elsewhere [21]. Briefly, polyclonal IgG was
purified from plasma, adjusted to a concentration of 30.0mg/mL
in incomplete RPMI 1640, and tested for biological activity
against both the 3D7 and FVO strains of Plasmodium falciparum.
Both strains are heterologous to those used in the construction of
the vaccines–T9/96 in the ME TRAP construct, and K1 for
PEV3A. A standardized GIA assay with samples from all
volunteers on the day of challenge was performed and was
compared with activity in samples from day 0.
Crisis Forms Further analysis of blood films from each
volunteer was undertaken. The blood film from the time of
diagnosis, and the preceding five films were selected. One of the
two microscopists examined each film in its entirety (1000 high
power fields), recorded the number of parasites seen, and
commented on their morphology. The microscopists were
blinded to the group allocation of the volunteers during this study.
Sequencing Parasite DNA was extracted from blood sample
from volunteer 525 on day 20 as described [17]. Primers were
designed to give a PCR product of 517 base pairs, which included
the region coding for the AMA-1 peptide in PEV3A. The PCR
products were purified and cloned into E. coli cells. DNA purified
from five of these clones was sequenced.
Sample size
This study aimed to provide both an initial estimate of the efficacy of
the vaccines used in combination and to compare this with the single
vaccine PEV3A. Prior to this trial, it was difficult to estimate the
potential size of any beneficial effect of PEV3A. The analysis of
overall efficacy in the 24 vaccinated volunteers had 80% power to
detect a significant difference from the six controls in rate of sterile
protection if 60% efficacy was achieved. Volunteers were allocated to
groups by the investigators. Neither volunteers nor the investigators
performing the study were blinded to the intervention given.
Statistical methods
The main analysis for the primary objective was based on the
number of hours between infectious challenge and blood stage
Malaria Blood Stage Efficacy
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parasitaemia. Each of the groups was compared with the other and
with the control group using the Kaplan Meier method. Statistical
significance of any differences observed was then assessed by the log
rank test. Further analysis of parasite growth rates was undertaken
using Mann Whitney U tests to compare groups. The secondary
objective, safety and tolerability, is descriptive. Immunogenicity was
assessed by comparing the geometric means of summed interferon-c
ELISPOT responses to malaria peptides. The geometric mean and
95% confidence intervals of the antibody titres determined by
ELISA and IFA in the two different vaccination groups were
calculated separately for each time point and study group. The
statistical significance of the effect of combined vaccine delivery was
determined using a Mann-Whitney U test to compare ELISA and
IFA titres between the two vaccination groups. The impact of co-
administration of vaccines on antibody avidity was calculated with a
two-tailed unpaired t test comparing avidities after first, second, and
third immunisation. The statistical significance of the difference in
number of responders after three vaccinations in the two groups was
calculated with a Fisher’s exact test. To assess the statistical
significance of titre increases (ELISA, IFA) after sporozoite challenge
we used a Wilcoxon signed-rank test to compare titres before and
after sporozoite challenge. Results were analysed for correlation to
any delay in parasitaemia. All data, including adverse event data
collected on StudyBuilder, were imported into and analysed using
Microsoft Excel or SPSS statistics packages. All statistical analyses
and graphs of ELISA, IFA and avidity results were made using
GraphPad Prism version 4.03 for Windows, GraphPad Software,
San Diego California USA.
RESULTS
Participant flow
The participant flow is shown in the CONSORT flowchart in
Figure 2. In total, 44 subjects were screened, of whom 13 were
excluded, 7 because they were ineligible (previous history of
intravenous drug use (IVDU), history of psychiatric illness, a new
finding of heart murmur, recent travel to endemic areas), and 6
withdrew consent after screening. 30 volunteers were initially
enrolled into the study. One of those enrolled into group 2 had an
undisclosed history of IVDU; this subject was withdrawn as soon as
this was revealed to the investigator, shortly after the first
vaccination. Data concerning the safety of one dose of vaccine was
collected from this volunteer, but they were otherwise excluded from
the analysis. One extra volunteer who had been screened but initially
not enrolled was then allocated to group 2 to replace this subject.
Recruitment
Recruitment began in August 2005, and the final visit took place
on 22nd February 2006.
Baseline data
Baseline demographic and clinical characteristics for all interven-
tion groups at entry into the trial are shown in Table 1.
Numbers analyzed
In total, 24 volunteers received all three vaccinations in groups 1
and 2. All of these volunteers subsequently took part in the malaria
challenge, and completed all follow up. 6 of the enrolled volunteers
were recruited to act as unvaccinated controls for the challenge
phase. One of these subjects was withdrawn from the challenge
early and treated; this was a result of an unforeseen change in
personal circumstances unrelated to the trial. This volunteer
subsequently completed all follow up. This subject, and the one
withdrawn after the first vaccination, accounted for the two
protocol deviations recorded during the trial.
Outcomes and estimation
Vaccine Potency and Safety The results of pre-trial potency
testing revealed that both FP9 and MVA ME-TRAP were as
immunogenic as expected based on previous assays of these
vaccines, producing on ELISPOT a mean number of 125 spot
forming units (sfu) per 106 splenocytes (standard deviation, SD
59.7), and 554 sfu/106 splenocytes (SD 118) respectively (mean of
results from 4 individual mice for each vaccine).
There were no clinically significant changes in haematological (full
blood count) or biochemical (sodium, potassium, urea, creatinine,
ALT, alkaline phosphatase, albumin, bilirubin) parameters through-
out the study. No serious adverse events occurred during this study.
One volunteer developed an enlarged right supraclavicular lymph
node following the first vaccination with FP9 ME-TRAP. The
maximum recorded size of this lymph node was 1.3cm. It increased
in size again following subsequent vaccinations in the right arm. This
node was still present at study close out. The volunteer was referred
to their General Practitioner for assessment and investigation, who
has indicated that no further follow up is required. Adverse events
following vaccination followed a profile similar to that seen before
with these vaccines [15]. The frequency of vaccination site pain,
swelling, redness, warmth, itch and scaling was, as expected, higher
following the intradermal administration of FP9 and MVA ME-
TRAP than with the intramuscular administration of PEV3A. One
volunteer (N514, in group 1) reported severe pain following the third
vaccination with PEV3A. This was recorded as starting on the
evening of the third vaccination, and lasting 6 days. It was recorded
as intensity 3 (severe pain at rest) for two days, and then subsided to
intensity 2 (pain on movement) for a further two days. For the final
two days it was recorded with a score of 1 (pain on touch). After this
period it had completely resolved, with no long term effects. The
frequency of general symptoms in group 1 was also lower than that in
group 2. In group 1, 50% of volunteers experienced at least one
systemic side effect (5/12 = 41% after dose 1, 1/12 = 8% after dose
2, and 2/12 = 17% after dose 3), whilst 83% (10/12) in group 2
experienced at least one (6/13 = 46% after dose 1, 7/12 = 58% after
dose 2, 9/12 = 75% after dose 3). This is slightly different to
previously reported studies using similar viral vectored vaccines,
where general symptoms seemed to be attenuated following second
and subsequent doses [15]. See tables 2 and 3 for details of adverse
events considered related to vaccination.
Immunogenicity
1. Antibody responses Anti-AMA49-C1 antibodies were
induced at high levels in all volunteers following immunisation
with PEV3A (Figure 3A). One immunisation was sufficient to
produce 100% seroconversion in both groups. No increase in anti-
peptide titres was observed after sporozoite infection. Unvaccinated
controls did not show any increase in anti-AMA49-C1 antibody
titres. Co-administration of FFM ME-TRAP led to an increase of
anti-peptide IgG titres, which became significant after the third
immunisation (Mann Whitney U; two-tailed p = 0.03). The avidity of
this anti-peptide response increased following every vaccination
(Figure 3B). The mean avidity index did not differ between the two
vaccination groups at any time point, however the increase of avidity
after three immunisations was significantly higher in the PEV3A
group (two-tailed unpaired t test p = 0.03). Sporozoite challenge led
to a decrease of avidity in group 1 (two-tailed paired t test p = 0.004),
whereas no significant change was observed in the group receiving a
combination of the two vaccines (two-tailed paired t test p = 0.6).
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Antibody reactivity with blood stage parasites was assessed by IFA
with P. falciparum (strain K1) blood stage parasites (Figure 4A). Three
immunisations with PEV3A led to an increase in parasite reactive
IgG titres in 4/12 volunteers in group 1 and in 2/12 volunteers in
group 2. Mean IgG titres in IFA after three immunisations did not
significantly differ between the two groups (Mann-Whitney U two-
tailed p = 0.49). There was no evidence of a difference in number of
responders after three vaccinations between group 1 and 2 (Fisher’s
exact test p = 0.64). Although not statistically significant, we observed
an increase in blood stage parasite-binding antibodies in IFA after
Figure 2. CONSORT Flow Chart
doi:10.1371/journal.pone.0001493.g002
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sporozoite challenge. 78% (7/9) of all volunteers IFA positive after
immunisation (both groups) had an increased endpoint titre after
sporozoite infection. Unvaccinated controls did not produce
detectable levels of blood stage parasite-binding antibodies (data
not shown). Generally, interpretation of IFA results with blood stage
parasites was very difficult due to non-specific background staining.
As we considered only clearly positive results, we may have missed
parasite-binding antibody responses in some volunteers. Western
blot analysis with sera from immunised volunteers (after three
vaccinations) showed specific recognition of parasite-derived AMA-1
in 16 out of 24 volunteers at a serum dilution of 1:100 (data not
shown) supporting the notion that we may have missed some parasite
cross-reactive responses in IFA.
High levels of anti-UK-39 antibodies were detected after
vaccination with PEV3A (Figure 3A). Two immunisations were
required to achieve 100% seroconversion in both vaccination
groups. Co-administration of FFM ME-TRAP had no impact on
the magnitude of mean anti-UK-39 titres at any time-point
(Mann-Whitney U two-tailed p = 0.95 after 3rd vaccination).
Sporozoite challenge led to an increase in anti-peptide titres in
the combination group (Wilcoxon sign-rank p = 0.03), whereas no
change in titre was seen in the PEV3A group after infection
(Wilcoxon sign-rank p = 0.64), (Figure 3A). No anti-UK-39 IgG
was detected in unvaccinated controls. The avidity of anti-UK-39
IgG increased following every immunisation (Figure 3B). Although
there was a higher mean avidity index in group 1 compared to
Table 1. Demographic characteristics
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Group N Mean AGE (SD) Min AGE Max AGE No. FEMALE (%) No. MALE (%)
Group 1 12 25.8 (4.3) 21 33 6 (50) 6 (50)
Group 2 13 29.5 (5.3) 23 44 5 (38) 8 (62)
Controls 6 30 (7.5) 23 40 3 (50) 3 (50)
TOTAL COHORT 31 21 44 14 (45) 17 (55)
doi:10.1371/journal.pone.0001493.t001..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Table 2. Frequency of solicited local symptoms after each
vaccine dose
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
VACCINE DOSE 1 Group 1, n = 12 Group 2, n = 13
PEV3A i.m. PEV3A i.m. FP9 ME-TRAP i.d.
n % n % n %
Pain 3 25 3 23 6 46
Redness 2 17 2 15 13 100
Swelling 2 17 1 8 11 85
Warmth 0 0 0 0 3 23
Itch 0 0 1 8 4 31
Scaling 0 0 0 0 7 54
VACCINE DOSE 2 Group 1, n = 12 Group 2, n = 12
PEV3A i.m. PEV3A i.m. FP9 ME-TRAP i.d.
n % n % n %
Pain 5 42 7 58 9 75
Redness 2 17 0 0 12 100
Swelling 1 8 0 0 11 92
Warmth 0 0 0 0 1 8
Itch 0 0 0 0 5 42
Scaling 0 0 0 0 7 58
VACCINE DOSE 3 Group 1, n = 12 Group 2, n = 12
PEV3A i.m. PEV3A i.m. MVA ME-TRAP i.d.
n % n % n %
Pain 8 67 8 67 12 100
Redness 2 17 2 17 12 100
Swelling 1 8 0 - 12 100
Warmth 0 - 0 - 10 83
Itch 0 - 0 - 8 67
Scaling 0 - 0 - 12 100
doi:10.1371/journal.pone.0001493.t002..
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Table 3. Frequency of solicited general symptoms after each
vaccine dose
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
VACCINE DOSE 1 Group 1, n = 12 Group 2, n = 13
n % n %
Documented Fever .37.5 1 8 0 -
Symptoms of feverish 2 17 4 31
Malaise 0 - 4 31
Arthralgia 2 17 2 15
Headache 0 - 4 31
Myalgia 5 83 5 38
Nausea/vomiting 0 - 0 -
VACCINE DOSE 2 Group 1, n = 12 Group 2, n = 12
n % n %
Document. Fever .37.5 0 - 0 -
Symptoms of feverish 1 8 4 33
Malaise 1 8 5 42
Arthralgia 1 8 1 8
Headache 0 - 3 25
Myalgia 3 25 6 50
Nausea/vomiting 0 - 1 8
VACCINE DOSE 3 Group 1, n = 12 Group 2, n = 12
n % n %
Documented Fever .37.5 1 8 1 8
Symptoms of feverish 1 8 4 33
Malaise 1 8 5 42
Arthralgia 1 8 3 25
Headache 0 - 3 25
Myalgia 2 17 5 42
Nausea/vomiting 0 - 1 8
doi:10.1371/journal.pone.0001493.t003..
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group 2 after second and third immunisation (two-tailed unpaired
t test p = 0.001 after second and p = 0.008 after third vaccination)
we did not observe any difference in avidity increase between the
two vaccination groups (after 3rd vaccine; two-tailed unpaired t test
p = 0.6), or a significant change in avidity after sporozoite challenge
(two-tailed paired t test group 1 p = 0.64; group 2 p = 0.44).
Immunisation with PEV3A alone induced parasite cross-reactive
antibodies in all volunteers after two vaccinations, as observed in IFA
with P. falciparum sporozoites (Figure 4B). The number of volunteers
with parasite-binding antibodies in the combination group increased
with every immunisation reaching 82% (9/11) after the third
immunisation. There was no significant difference in the number of
responders after three vaccinations between group 1 and 2 (Fisher’s
exact test p = 0.22). Higher mean IFA titres induced by immunisa-
tion with PEV3A alone compared to combined vaccination became
significant after three vaccinations (Mann-Whitney U two-tailed
p = 0.02). A boost in vaccine-induced responses after infection was
observed in 33% (4/12; group 1) and 75% (9/12; group 2) of the
volunteers as detected by increased IFA titres after sporozoite
challenge. The observed increase of IFA titres after infection was
significant only for the group receiving both vaccines (Wilcoxon sign-
rank p = 0.04). No sporozoite-binding antibodies were detected in
unvaccinated controls after sporozoite challenge (data not shown).
Western blot staining of a CSP characteristic double band was seen
in 13 out of 23 sera following vaccinations at a dilution of 1:100 (data
not shown). There was no correlation in the level of any induced
antibodies with time to infection.
2. T cell responses There were low level background
responses to ME-TRAP in group 1 (summed response at peak
time point was 13.3 SFU/106 PBMC). Responses in group 2 were
significantly higher than those in group 1. The geometric mean
summed responses to ME and T996 TRAP pools at peak time
point was 50 SFU/106 PBMC (two-tailed t test on log converted
data p = 0.001). However these responses were low compared to
those seen in previous trials with this vaccine (previously, a
geometric mean summed response to ME-TRAP of 454 SFU/106
PBMC was observed at the peak time point).
Efficacy
1. Number of infected hepatocytes A model based on
Hermsen et al. [18] allows the number of infected hepatocytes
for each individual to be estimated. Compared to the control
group the estimated number of infected hepatocytes was 1.8 times
lower in the PEV3A group and 2.3 times lower in the combination
group respectively (Figure 5). Statistical analysis of these estimates
showed no significant difference between group 1 and group 2
(Mann Whitney U test, p = 0.6), or between either group of
vaccinated volunteers and controls (group 1 versus controls, Mann
Whitney U test, p = 0.3, group 2 versus controls, p = 0.4; all
vaccinated volunteers versus controls, Mann Whitney U, p = 0.3).
2. Development of parasitaemia Mean time to parasitaemia
for controls (n = 5) was 11.8 days (S.D. 1.6 days), compared to
12.75 days for group 1 (n = 12, S.D. 2.68 days), and 12.1 days for
group 2 (n = 12, (S.D. 0.96 days). A Kaplan Meier plot of survival is
shown in Figure 6. One volunteer in group 1 was not diagnosed until
day 20, however, there is no significant difference in time to
parasitaemia for volunteers in either vaccination group compared to
controls (Log rank = 0.87, p = 0.65).
Figure 3. Anti-peptide responses. A. (Upper panel) Geometric mean anti-AMA49-C1 (PEV301) and anti UK-39 (PEV302) endpoint-titres (log10) with
95% confidence intervals for group 1 (PEV3A), group 2 (PEV3A+ME-TRAP) and unvaccinated controls. B. (Lower panel) Mean avidity increase (relative
to avidity index after first immunisation) with 95% confidence intervals. Arrows along the x axis represent the timing of each vaccination, and the
asterisk denotes the challenge.
doi:10.1371/journal.pone.0001493.g003
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Examples of estimated parasite densities based on PCR data are
shown in Figure 7. Most volunteers showed an exponential
increase in parasite densities starting at day 7 after challenge
(Figure 7A). However, a number of subjects (N525 and N529 in
group 1 and N513 and N532 in group 2), had unusual PCR results
(Figure 7B). In these volunteers PCR for parasite DNA was
positive at low levels (known to be undetectable by microscopy)
and was then negative before becoming positive again, at least
once, before rising up to the point of diagnosis.
3. Growth rates The mean rate of blood stage parasite growth
in volunteers in group 1 was 5.7 parasites per mL per cycle (95%
confidence intervals 4.1–7.3; standard deviation 2.6), for group 2 this
was 6.3 (95% CI 4.0–8.5; SD 3.5) and for controls it was 8.7 (95% CI
7.2–10.2; SD 1.2) (Figure 8). Comparing the growth rates of
vaccinated volunteers, those in group 1 are not significantly different
to those of volunteers in group 2 (Mann Whitney U test; two-tailed
p = 0.63). Comparing group 1 to controls, growth rates are
significantly lower in group 1 volunteers than in controls (Mann
Whitney U; two-tailed p = 0.02). For group 2 versus controls, this is a
significant reduction (Mann Whitney U; two-tailed p = 0.02).
Grouping all vaccinated volunteers together, and comparing them
to controls, there is again a significant reduction in parasite growth
rates; (Mann Whitney U; two-tailed p = 0.012).
4. Crisis forms During the challenge phase, microscopists
detected the presence of morphologically abnormal parasites in films
from volunteers pre-diagnosis. These differ from normal parasites in
the staining of the nuclear material. While live parasites have nuclei
that stain red/blue, these abnormal parasites stained only blue (see
Figure 9). We hypothesised that these were ‘crisis forms’ [22] and
that they might represent an effect of vaccine-induced blood stage
immunity. Morphologically abnormal parasites were seen in films
from every vaccinated volunteer (n = 24) in this study. They were
identified in the films of significantly fewer (2/6) controls (Fisher’s
exact test, p = 0.001). As a proportion of crisis forms among all
parasites detected, in group 1, the average was 66% (95% CI, 54–78,
SD 19), for group 2, the proportion was 55% (95% CI, 41–69, SD
Figure 4. Antibody reactivity with P. falciparum. A. (Upper panel) IgG endpoint titres measured in IFA with P. falciparum (K1) blood stage parasites.
B. (Lower panel) IgG endpoint titres measured in IFA with P. falciparum (NF54) sporozoites. Sera were tested before vaccination, after every
vaccination and after sporozoite challenge. Individual titres and the geometric mean for every time point are shown on a log scale.
doi:10.1371/journal.pone.0001493.g004
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22) and for controls the proportion was 13% (95% CI 211–37, SD
23). The proportion of crisis forms among all detected parasites in
vaccinated volunteers was significantly greater than in controls
(Mann Whitney U, p = 0.001).
Ancillary analyses
1. Growth Inhibition Assay No significant GIA activity was
seen in any sample relative to day 0 activity.
2. AMA-1 sequencing Volunteer 525 remained undiagnosed
until day 20 after the challenge and then became blood film positive.
The possibility that this could result from parasite immune escape
was considered. Vaccination-induced mutations in another
Plasmodium antigen have been described in monkeys after relatively
short periods of infection [23]. We sequenced the AMA-1 gene from
DNA extracted from a blood sample from volunteer 525 on the day
of diagnosis (day 20) but found no sequence changes.
DISCUSSION
This trial is the first to provide evidence of vaccine-induced blood
stage anti-parasite efficacy and partial protection in a healthy
volunteer challenge study. Two observations are indicative of a
parasite inhibitory effect.
The first of these may be divided into three components. (I.i)
One volunteer was not diagnosed until day 20 after infection, this
being a substantial delay in time to diagnosis. In 52 non-
vaccinated control volunteers involved in identical challenge
studies at the centre over the last six years, none have remained
parasite free on microscopy beyond day 14 post challenge. (I.ii)
The same volunteer, along with three others, had fluctuations in
PCR-measured parasite densities that are consistent with a blood
stage inhibitory effect on parasite growth. (I.iii) There was a
significant difference in the parasite growth rates in vaccinated
volunteers versus controls. This is observed in both groups of
vaccinated volunteers, and is therefore likely to be related to
vaccination with PEV3A.
The second observation relates to the presence of morpholog-
ically abnormal parasites suggests a vaccine-induced immune
response against the parasites. Malaria parasite crisis forms were first
described in P. brasilianum infection of Cebus monkeys 1944 by
Taliaferro, WH et al. [22]. They have since been described in mouse
[24] and human malarias [25]. A study by Jensen et al. [26]
demonstrated induction of crisis forms in cultured P. falciparum with
human immune serum from Sudan. Historically, these abnormal
parasites have not been observed in studies at this centre before.
However, as they were also observed in the blood of two of six
control volunteers, their presence is not necessarily vaccine related.
The volunteer in whom diagnosis was delayed until day 20
developed high levels of anti AMA49 and UK39 antibodies (peak
AMA49 response end point titre 33779, UK39 endpoint titre
18102). Positive IFA results were obtained with sporozoites, but
Figure 5. Number of infected hepatocytes. Estimated numbers of
infected hepatocytes for individual volunteers are shown. Lines
represent the geometric mean for each group with IQ ranges.
doi:10.1371/journal.pone.0001493.g005
Figure 6. Kaplan Meier Survival curve. A Kaplan Meier plot showing time to diagnosis of malaria for each group of volunteers after the challenge.
doi:10.1371/journal.pone.0001493.g006
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not with blood stage parasites. ELISPOT responses were
negligible, with AMA-1 and NANP responses all remaining ,10
sfu/106 PBMC throughout the study. No detectable GIA activity
was measured.
Taken together these results suggest that PEV3A has induced a
protective immune response against blood stage parasites.
However this was not sufficient to prevent patent infection in
malaria naı¨ve individuals in the stringent challenge model used
that involves high numbers of sporozoites for infection. Blood stage
protection might be enhanced by targeting several blood stage
antigens with a multivalent subunit vaccine and this is technically
feasible with the virosomal vaccine approach.
This study was designed to search for a possible synergistic effect
of combining two potentially complimentary vaccine strategies.
The idea that combining induction of anti-sporozoite antibodies
by the CS component of PEV3A and anti-liver-stage T cell
responses by recombinant viruses would lead to a synergistic
enhancement of protection was suggested by experiments in a
Figure 7. PCR data. Number of parasites per mL, estimated using a calibration curve, plotted by day post sporozoite challenge. A. Three volunteers
selected to demonstrate expected pattern of PCR results: an exponential increase in the numbers of parasites over time, with some cycling seen as
parasites are sequestered and released. B. This figure shows data from all 4 volunteers who had unusual PCR results. Up to 150 parasites/mL are
detected, and are subsequently undetectable for one or more time points, before they are measured again. This pattern occurs several times, up to a
maximum of 5 times in volunteer N525.
doi:10.1371/journal.pone.0001493.g007
Figure 8. Growth rates, mean and IQ ranges, by group. Growth rate (parasites per mL per cycle) for each individual is shown; the lines represent the
group means and inter quartile ranges.
doi:10.1371/journal.pone.0001493.g008
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mouse model [5]. In this model, viral vectors appeared to act as an
adjuvant to a protein vaccine, enhancing the magnitude of the
antibody response. The best results (i.e. highest levels of protection
from a subsequent malaria challenge) were obtained when the
vaccines were mixed physically in the same syringe and
administered at the same site. Both T cells and antibodies were
shown to be important in mediating this protection. In this first
phase I/IIa trial, we elected to administer the vaccines at the same
time, but at separate sites rather than mixed in the same syringe.
This was in order to reduce the potential risk of interference of the
two vaccines. The vaccines used were safe when administered
concurrently, in opposite arms, and the PEV3A virosomes were
immunogenic. High levels of anti-AMA49-C1 and anti-UK-39
antibodies were measured post vaccination in all volunteers. A
high proportion of these antibodies were able to bind to the native
parasite proteins in vitro in IFA suggesting they are likely to be
functional. There was some discrepancy between IFA positivity
and the results of Western blot analysis. This appears to be related
to high levels of background staining in the IFA with blood stage
parasites in many of the volunteers on day 0, probably caused by
cross-reactive antibodies. The observed ELISA titres were
comparable with those from a previous Phase I study using this
vaccine [14]; (Okitsu et al. submitted). Co-administration of FFM
ME-TRAP did boost the magnitude of the anti-AMA49-C1
antibody response but not the anti-UK-39 response. However,
whereas in the animal model, good T cell induction was achieved
by the viral vectored vaccines this was reduced about 10-fold in
this study compared to previous trials. Co-administration of
vaccines could have led to antigenic competition or interference,
which might account for this low immunogenicity. Both FP9 and
MVA ME-TRAP were tested for potency in mice prior to the
study, and were found to be potent, and slightly more
immunogenic than previously used batches of this vaccine (data
not shown). Estimated numbers of P. falciparum infected hepato-
cytes were similar between both groups of vaccinated volunteers,
leading to the conclusion that there was no clear evidence of any
Figure 9. Normal parasites and crisis forms. Crisis forms differ from normal parasites in their slightly more ‘ragged’ morphology and altered staining
of the nuclear material-live parasites have nuclei that stain red/blue, these abnormal parasites lose all red chromatin staining. Magnified high power
images are shown in A&B. Normal parasites are seen in Figure 9A, whilst 9B shows a film containing a crisis form. The remaining films are unmagnified
and white blood cell nuclei are clearly visible in blue, with smaller headphone shaped parasites. Figure 9C & D show single crisis forms, whilst 9E & F
show multiple normal parasites, with the characteristic red/blue nuclear staining.
doi:10.1371/journal.pone.0001493.g009
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liver stage effect by FFM ME-TRAP, in keeping with the low T
cell immunogenicity observed.
Another important observation in this study was an increase in
parasite reactive antibodies after sporozoite challenge. While anti-
peptide titres did not markedly change, titres measured in IFA with
P. falciparum blood stage parasites and sporozoites were boosted by
infection. This indicates that PEV3A-induced immune responses can
be boosted and skewed towards parasite-binding antibody popula-
tions by sporozoite infection. Results from in vitro sporozoite
inhibition assays in a phase 1 trial with the same vaccine have
shown inhibition of sporozoite migration and invasion in the
presence of anti-UK-39 IgG (Okitsu et al., submitted). Although
statistically not significant, we found a trend towards reduced
numbers of infected hepatocytes in both vaccination groups
compared to unvaccinated controls, possibly suggesting a role for
anti-UK39 antibodies in the reduction of infected hepatocytes, but
there was little power in this inter-group comparison.
Reduced parasite growth rates and the presence of crisis forms
in the blood of all vaccinated volunteers who took part in this trial
provide evidence that the immune response to the vaccine PEV3A
is exerting an anti-blood stage protective effect. Murine monoclo-
nal antibodies against AMA49-C1 are capable of inhibiting blood
stage parasite growth in vitro [11], which is at least in part due to
inhibition of intra-erythrocytic parasite development (unpublished
observation).
The interpretation of these results is complicated by the fact that
AMA-1 is expressed by both sporozoites and merozoites [27], and so
it is possible that antibodies to this antigen induced by the virosome
might have contributed to any pre-erythrocytic effect. The non
significant trend to reduced numbers of parasites emerging from the
liver of all vaccinated volunteers may reflect this.
It might be argued that these observations of blood stage
immunity (reduction in growth rates, presence of crisis forms etc.)
may rather be related to the potential pre-erythrocytic action of
PEV3A. However, in previous challenge studies, the number of
parasites emerging from the liver of unvaccinated control
volunteers has been shown to vary as much as five fold [7].
Despite this variation, rates of parasite growth in these volunteers
were similar. Equally, crisis forms have never been observed
historically in our studies of pre-erythrocytic vaccine candidates.
Indeed, following their observation in this study, the same slide
reader went back to examine a selection of blood films from
vaccinated and control volunteers in two previous studies where
some evidence of pre-erythrocytic efficacy has been observed
(VAC021 [28] and VAC023 [29]). The slide reader was blinded to
the group allocation of the volunteers. In total 72 slides were
selected for re-examination (6 slides each from 6 volunteers from
each study, 3 vaccinees plus 3 controls) and no crisis forms were
observed. It seems likely therefore, that the differences observed
here are indeed related to vaccine induced blood stage immunity.
The current challenge was a heterologous one with 3D7 parasites,
rather than the K1, or T9/96 strains, used in the generation of
PEV3A or the ME-TRAP vaccines respectively. PEV301 targets the
semi-conserved sequence AMA-1446-490, which contains only three
dimorphic positions (D/N448, M/K451 and K/I485) at its C and N
terminus, respectively. The elicited antibody responses are focussed
on the conserved central portion of this sequence stretch and all
murine vaccine-induced monoclonal antibodies tested were cross-
reactive with P. falciparum strains expressing natural sequence
variants of AMA-1446-490 [11]. In contrast to results with monoclonal
antibodies, growth inhibition assays performed with sera of the
volunteers immunised in this trial were negative. Further data will be
required to assess the utility and sensitivity of this assay for predicting
blood stage vaccine efficacy, but these trial results suggest caution in
the exclusive use of this assay as an in vitro predictor of blood-stage
vaccine efficacy.
An effective malaria vaccine may need to target multiple
parasite antigens from different stages of the life cycle. Several
vaccine candidates have previously provided evidence of pre-
erythrocytic stage efficacy in phase IIa trials [8,30,31,32]. Here we
have shown evidence for a vaccine-induced blood stage protection
for the first time in a challenge study. This study also shows that
protective efficacy at the blood-stage level can be observed using
sporozoites rather than blood stage parasites [33] for challenge
studies. Moreover, 100% seroconversion induced by virosomally-
formulated peptides and the observed boost of this response by
sporozoite infection support the potential of further development
of the virosome system as a malaria vaccine.
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